USPTO serial 79288175
SOSEI HEPTARES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 30, 2022
- Examiner
- ROSEN, BENJAMIN H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SOSEI HEPTARES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical products and proteins for manufacturing chemical and biological pharmaceutical products; chemical products and proteins for the scientific research of chemical and biological pharmaceutical products; chemical products and proteins for diagnostic use, except medical or veterinary uses, namely, diagnostic preparations for scientific use; proteins and specifically proteins in the nature of G-protein-coupled receptors for manufacturing pharmaceutical products; proteins and specifically proteins in the nature of G-protein-coupled receptors, for the scientific research of pharmaceutical products; chemicals and proteins for chemical and biological drug discovery, lead identification and diagnostics, namely, chemical and biological preparations for use in scientific purposes; proteins and G-protein-coupled receptors for drug discovery purpose, namely, proteins and biological preparations for use in scientific research; chemicals preparations and biologicals preparations for scientific research purposes, being proteins, transmembrane proteins and G proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, for chemical and biological drug discovery, lead identification and diagnostics; proteins, including transmembrane proteins and G-proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, all for use in scientific pharmaceutical research and scientific pharmaceutical research in the nature of drug discovery purposes | ACTIVE | — |
| 005 | Biological products for medical use in chemical and biological drug discovery, lead identification and diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological products for therapeutic purposes, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; proteins for medical use in chemical and biological drug discovery, lead identification and diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; medicines, namely, diagnostic preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; cleaning agent for medical use, namely, medical cleansers for skin wounds; biological formulation for medical use in developing chemical and biological pharmaceutical products, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological formulation for medical use in identifying lead chemical and biological products, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological formulation for medical diagnostic use, namely, diagnostic preparations for medical use; biological formulation for therapeutic use, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; proteins and G-protein-coupled receptors for medical use in drug discovery; biologicals and small chemical entities, including proteins, G-protein-coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for therapeutic purposes, namely, diagnostic preparations for medical use; proteins, G-protein-coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for use in medical diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; medical oiled paper; drug delivery agents in the form of edible pharmaceutical wafers for wrapping powdered pharmaceuticals; gauze for dressings; specialized capsules for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; eye patches for medical purposes, ear bandages; menstrual bands being sanitary pads; menstrual tampons; menstrual napkins, namely, menstrual symptom treatment preparations; menstrual underwear, namely, panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; collodion for pharmaceutical purposes; cotton swabs for medical purposes; breast-nursing pads | ACTIVE | — |
| 042 | Bio-technology, pharmaceutical and scientific testing, research and development; biological research services; research and development services in the pharmaceutical and biopharmaceutical fields;, research and development services in the pharmaceutical and biopharmaceutical fields, namely, in the field of technologies related to proteins and G-protein-coupled receptors; research services in biology and chemistry fields; pharmaceutical research services in chemical and biological drug discovery and development; scientific and pharmaceutical research and development services for identifying lead chemical compounds; scientific analysis and research services in medicinal and synthetic chemistry; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; pharmaceutical research and development in the nature of research, creation, development and provision of chemical and biological drug targets for non-medical scientific screening purposes; technical diagnostic testing services, namely, scientific and pharmaceutical research and development; scientific research, analysis and examination for identification of compounds through automated screening processes, being scientific and pharmaceutical research and development; research and development services in chemical and biological pharmaceutical development; provision of information, advisory services and consultancy relating to the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sosei Group Corporation
- Other trademarks owned by Sosei Group Corporation
- Other trademarks owned by Nxera Pharma Co., Ltd
- Other trademarks owned by Sosei Group Corporation
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named SOSEI HEPTARES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 14, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Dec 27, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 7, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 7, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 30, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 4, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 30, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 30, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 5, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 14, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 14, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 8, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 8, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 25, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 5, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 5, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 5, 2022 | ALIE | ASSIGNED TO LIE | — |
| Apr 30, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Mar 14, 2022 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 19, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 1, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 1, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 9, 2021 | GRML | CORRESPONDENCE E-MAILED | — |
| Sep 9, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 9, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 9, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 9, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 5, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 5, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 4, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 4, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 4, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 11, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 11, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 3, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 2, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 30, 2020 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Jun 30, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 30, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 29, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 26, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 26, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 25, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |